Article

Isis appoints Dr. Jonas as executive vice president

Carlsbad, CA-Jeffrey M. Jonas, MD, joined Isis Pharmaceuticals Inc. Feb. 1 as executive vice president. He will lead clinical development, preclinical development, regulatory affairs, quality assurance, and compliance at the company.

Carlsbad, CA-Jeffrey M. Jonas, MD, joined Isis Pharmaceuticals Inc. Feb. 1 as executive vice president. He will lead clinical development, preclinical development, regulatory affairs, quality assurance, and compliance at the company.

Dr. Jonas will be broadly responsible for the entire pipeline, both partnered and unpartnered, and contribute to portfolio management. In addition, he will be a principal representative of the company, interacting with investors and partners, working with Kate Corcoran, PhD, vice president, corporate development.

Prior to joining Isis, Dr. Jonas was chief medical officer and executive vice president at Forest Laboratories Inc., where he was responsible for clinical development, medical affairs, pharmacovigilence, and external scientific affairs.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.